(Q53462605)

English

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

anticoagulation

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Stephan Glund

1

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Joachim Stangier

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Michael Schmohl

3

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Dietmar Gansser

4

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Stephen Norris

5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Joanne van Ryn

6

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Benjamin Lang

7

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Steven Ramael

8

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Viktoria Moschetti

9

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Fredrik Gruenenfelder

10

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Paul Reilly

11

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Jörg Kreuzer

12

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

language of work or name

0 references

publication date

15 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

386

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

9994

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

680-690

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Urgent reversal of vitamin K antagonist therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Warfarin reversal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Management and outcomes of major bleeding during treatment with dabigatran or warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A specific antidote for dabigatran: functional and structural characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Calibrated automated thrombin generation measurement in clotting plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of PER977 to reverse the anticoagulant effect of edoxaban

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960732-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)60732-2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26088268

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53462605&oldid=1749510374"